Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study

Eva Domingo Domenech, Carla Marco, Eva Maria Gonzalez Barca, Cristina Muniesa, Patricia Lopez-Pereira, Ana C. De Oliveira, Carmen Aguilera, German Ferrer, Anna Maria Sureda Balari, Roser Velasco

Blood (2023) 142 (Supplement 1): 6186.

https://doi.org/10.1182/blood-2023-182348

Published: 2023

Journal Articles

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Jasson Villarreal Hernandez, Helena Pomares, Antonella Sturla, Esther Alonso, Clara Maluquer Artigal, Rebecca Andersson, María Alicia Senin, Maria Teresa Encuentra, Mercedes Galiano, Lurdes Zamora, Marta Cabezón, Neus Ruiz Xiville, Maria Carolina Florian, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5868.

https://doi.org/10.1182/blood-2023-187430

Published: 2023

Journal Articles

Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center

Nicolo Rampi, Montserrat Cortes-Romera, Patricia Lopez-Pereira, Carolina Martinez-Ramos, Clara Montane Carbo, Carolina Esther Arevalo Leon, Ana C. De Oliveira, Eva Maria Gonzalez Barca, Anna Maria Sureda Balari, Eva Domingo Domenech

Blood (2023) 142 (Supplement 1): 6216.

https://doi.org/10.1182/blood-2023-186195

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Blood (2023) 142 (Supplement 1): 4899.

https://doi.org/10.1182/blood-2023-181815

Published: 2023

Journal Articles

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 339.

https://doi.org/10.1182/blood-2023-186916

Published: 2023

Journal Articles

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Blood (2023) 142 (Supplement 1): 3324.

https://doi.org/10.1182/blood-2023-184837

Published: 2023

Journal Articles

Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study

Blood (2023) 142 (Supplement 1): 785.

https://doi.org/10.1182/blood-2023-179153

Published: 2023

Journal Articles

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 871.

https://doi.org/10.1182/blood-2023-185661

Published: 2023

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Maria Sureda Balari, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Ozcan, Amos Odeleye-Ajakaye, Nishitha Reddy, Patricia Marinello, Jane N. Winter

Blood (2023) 142 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2023-181171

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Blood (2023) 142 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2023-179829

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience

Nicolo Rampi, Maite Antonio, Eva Domingo Domenech, Patricia Lopez-Pereira, Ana C. De Oliveira, Carmen Aguilera, Anna Maria Sureda Balari, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2023-190136

Published: 2023

Journal Articles

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Blood (2023) 142 (Supplement 1): 3702.

https://doi.org/10.1182/blood-2023-185679

Published: 2023

Journal Articles

Help for Ukrainian Hematology Patients (HUP) - a Global Initiative Supporting the Establishment of Hematology Centers and Hematopoietic Cell Transplantation Programs in a Time of War

Blood (2023) 142 (Supplement 1): 264.

https://doi.org/10.1182/blood-2023-185883

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience

Frailty Syndrome in Adults Undergoing Autologous Hematopoietic Cell Transplantation. Prospective Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular

Help for Ukrainian Hematology Patients (HUP) - a Global Initiative Supporting the Establishment of Hematology Centers and Hematopoietic Cell Transplantation Programs in a Time of War

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only